Aplastic Anemia
Conditions
Interventions
Marrow and essence deficiency, and blood-heat syndrome:Bushentianjingliangxue decotion and Western medicine standard treatment drugs
Marrow and essence deficiency, the depletion of marrow, and blood occlusion syndrome:Bushentianjinghuoxue decotion and Western medicine standard treatment drugs
Spleen–Kidney?Qi-deficiency, marrow, and collaterals deficiency syndrome:Bushentianjingshexue decotion and Western medicine standard treatment drugs
western medicine cohort:Western medicine standard treatment drugs
Spleen?deficiency?and?dampness, marrow deficiency and phlegm?coagulation syndrome:Lingguizhugan decotion and Liujunzi decotion ,as well as Western medicine standard treatment drugs
Kidney deficiency and essence injury, marrow deficiency, and blood stasis syndrome:Wenshen Yangxue Huoluo Decoction and Western medicine standard treatment drugs
Qi and blood weakness, marrow deficiency, and blood stasis syndrome:Dangguibuxue and Siwu decotion ,as well as Western medicine standard treatment drugs
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Eligibility
Sex/Gender
All
Age
16 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria for aplastic anaemia; 2) The patient's age range is 16 to 80 years old; 3) No standard regimen has been used for treatment after the first diagnosis, or the current regimen has been maintained for more than 3 months; 4) Sound liver and kidney function (creatinine ?1.5*ULN, BUN ?1.5*ULN, ALT ?2*ULN, AST ?2*ULN, total bilirubin ?1.5*ULN); 5) Able to comply with the study visit schedule and understand and comply with all trial protocol requirements; 6) Able to understand and voluntarily sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1) Combination of PNH clones; 2) Allergy to herbal medicinal tablets; 3) Severe cardiac disease, including New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled hypertension or hypotension, or severe valvular or endocardial disease resulting in a risk of thromboembolism in the subject; 4) Clinically significant or uncontrolled persistent inflammatory/autoimmune disease (e.g., rheumatoid arthritis, Crohn's disease, ulcerative colitis, celiac disease, systemic lupus erythematosus, etc.); 5) Anticipated haematopoietic stem cell transplantation within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chinese Medicine Tongue and Pulse Information;treatment efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| four diagnostic information; | — |
Countries
China
Contacts
Public ContactBaodong Ye
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Outcome results
None listed